NGS HLAA2 assay clinical trials

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

This study is for people with advanced lung cancer that has stopped responding to certain immune system treatments. It tests a new treatment called OSE2101 against a standard chemotherapy, Docetaxel, to see which works better. This is a large study trying to find new ways to help patients.